Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

ZNTL Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.60%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $205,276.56

Zentalis Pharmaceuticals Insider Trading History Chart

Zentalis Pharmaceuticals Share Price & Price History

^$3.47

▼ -0.48 (-12.15%)

As of 11/15/2024 01:00 AM ET

Days: 30 | 90 | 365

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Zentalis Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/4/2024	Vincent Vultaggio	Insider	Sell	1,603	$3.18	$5,097.54	33,855
5/31/2024	Cam Gallagher	CFO	Sell	9,597	$11.98	$114,972.06	633,680
5/9/2024	Diana Hausman	Insider	Sell	3,356	$12.62	$42,352.72	373,876
2/12/2024	Cam Gallagher	President	Sell	1,173	$11.44	$13,419.12	643,277
2/12/2024	Melissa B. Epperly	CFO	Sell	2,573	$11.44	$29,435.12	451,449
11/13/2023	Kimberly Blackwell	CEO	Buy	5,000	$10.29	$51,450.00	254,800
11/10/2023	David Michael Johnson	Director	Buy	17,000	$9.88	$167,960.00	144,389
10/4/2023	Carrie Brownstein	Insider	Sell	10,628	$19.50	$207,246.00	105,685
10/4/2023	Melissa B. Epperly	CFO	Sell	5,482	$19.50	$106,899.00	387,691
9/11/2023	Jan Skvarka	Director	Sell	5,000	$25.05	$125,250.00	47,970
6/20/2023	Matrix Capital Management Comp	Major Shareholder	Buy	4,760,000	$22.66	$107,861,600.00	13,959,973
5/31/2023	Cam Gallagher	President	Sell	27,768	$26.27	$729,465.36	463,502
5/26/2023	Kevin D. Bunker	Insider	Sell	80,000	$30.02	$2,401,600.00	15,000
2/13/2023	Cam Gallagher	President	Sell	3,332	$20.42	$68,039.44	499,771
2/13/2023	Kevin D. Bunker	Insider	Sell	3,807	$20.42	$77,738.94	871,657
2/13/2023	Melissa B. Epperly	CFO	Sell	2,624	$20.42	$53,582.08	397,275
2/6/2023	Cam Gallagher	President	Sell	10,000	$22.27	$222,700.00	503,103
1/17/2023	Cam Gallagher	President	Sell	10,000	$24.15	$241,500.00	352,011
1/5/2023	Cam Gallagher	President	Sell	10,000	$21.02	$210,200.00	362,011
11/15/2022	Cam Gallagher	President	Sell	12,500	$22.77	$284,625.00	372,011
11/7/2022	Cam Gallagher	President	Sell	12,500	$23.67	$295,875.00	396,885
10/17/2022	Cam Gallagher	President	Sell	12,500	$23.51	$293,875.00	409,385
10/5/2022	Cam Gallagher	President	Sell	12,500	$22.32	$279,000.00	431,885
9/15/2022	Cam Gallagher	President	Sell	12,500	$25.26	$315,750.00	454,385
7/20/2022	Kevin D. Bunker	COO	Sell	5,000	$30.00	$150,000.00	100,000
7/13/2022	Kevin D. Bunker	COO	Sell	1,710	$30.02	$51,334.20	108,290
7/5/2022	Kevin D. Bunker	COO	Sell	25,000	$30.07	$751,750.00	110,000
4/11/2022	Kevin D. Bunker	COO	Sell	5,000	$30.55	$152,750.00	135,000
4/5/2022	Cam Gallagher	Director	Sell	10,000	$50.48	$504,800.00	355,813
4/4/2022	Anthony Y. Sun	CEO	Sell	10,471	$48.50	$507,843.50	1,175,589
4/4/2022	Melissa B. Epperly	CFO	Sell	17,080	$50.09	$855,537.20	247,414
3/21/2022	Kevin D. Bunker	COO	Sell	10,000	$49.07	$490,700.00
3/15/2022	Cam Gallagher	Director	Sell	10,000	$41.92	$419,200.00
3/10/2022	Kevin D. Bunker	COO	Sell	10,000	$46.94	$469,400.00
3/7/2022	Cam Gallagher	Director	Sell	10,000	$44.94	$449,400.00
3/1/2022	Anthony Y. Sun	CEO	Sell	10,471	$49.79	$521,351.09
2/23/2022	Melissa B. Epperly	CFO	Sell	1,913	$49.10	$93,928.30
2/22/2022	Kevin D. Bunker	COO	Sell	10,000	$49.09	$490,900.00
2/14/2022	Alexis Pinto	Insider	Sell	691	$50.23	$34,708.93
2/14/2022	Anthony Y. Sun	CEO	Sell	4,733	$50.23	$237,738.59
2/14/2022	Cam Gallagher	Director	Sell	7,188	$50.19	$360,765.72
2/14/2022	Dimitris Voliotis	SVP	Sell	601	$50.23	$30,188.23
2/14/2022	Kevin D. Bunker	COO	Sell	4,688	$50.26	$235,618.88
2/10/2022	Kevin D. Bunker	COO	Sell	10,000	$53.50	$535,000.00
2/7/2022	Cam Gallagher	Director	Sell	10,000	$53.45	$534,500.00
2/1/2022	Anthony Y. Sun	CEO	Sell	10,471	$57.58	$602,920.18
1/20/2022	Dimitris Voliotis	SVP	Sell	10,000	$60.63	$606,300.00
1/18/2022	Cam Gallagher	Director	Sell	10,000	$62.64	$626,400.00
1/10/2022	Kevin D. Bunker	COO	Sell	10,000	$68.41	$684,100.00
1/5/2022	Cam Gallagher	Director	Sell	10,000	$75.49	$754,900.00
1/3/2022	Anthony Y. Sun	CEO	Sell	10,471	$80.07	$838,412.97
1/3/2022	Kimberly Blackwell	Director	Sell	1,000	$83.74	$83,740.00
12/20/2021	Kevin D. Bunker	COO	Sell	10,000	$79.24	$792,400.00
12/15/2021	Cam Gallagher	Director	Sell	10,000	$74.03	$740,300.00
12/10/2021	Kevin D. Bunker	COO	Sell	10,000	$71.71	$717,100.00
12/6/2021	Cam Gallagher	Director	Sell	10,000	$71.33	$713,300.00
12/1/2021	Anthony Y. Sun	CEO	Sell	10,471	$77.98	$816,528.58
12/1/2021	Kimberly Blackwell	Director	Sell	1,000	$81.84	$81,840.00
11/22/2021	Kevin D. Bunker	COO	Sell	10,000	$75.99	$759,900.00

Trump’s Back, but DC’s Coming for Your Money!

From Genesis Gold Group | Ad

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

SEC Filings (Institutional Ownership Changes) for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Institutional Buying and Selling by Quarter

Zentalis Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	1,292,100	$4.76M	0.0%	-3.2%	1.813%
11/15/2024	Barclays PLC	75,395	$0.28M	0.0%	+18.5%	0.106%
11/15/2024	Y Intercept Hong Kong Ltd	12,303	$45K	0.0%	-88.2%	0.017%
11/15/2024	XTX Topco Ltd	194,062	$0.71M	0.1%	+8.7%	0.272%
11/15/2024	Jane Street Group LLC	161,193	$0.59M	0.0%	-6.8%	0.226%
11/15/2024	State Street Corp	1,246,613	$4.59M	0.0%	-59.2%	1.749%
11/15/2024	Quarry LP	15,000	$55K	0.0%	N/A	0.021%
11/15/2024	Paloma Partners Management Co	10,024	$37K	0.0%	N/A	0.014%
11/15/2024	Erste Asset Management GmbH	9,800	$37K	0.0%	N/A	0.014%
11/14/2024	PDT Partners LLC	107,159	$0.39M	0.0%	+166.0%	0.151%
11/14/2024	Verition Fund Management LLC	1,504,320	$5.54M	0.0%	+172.1%	2.115%
11/14/2024	Capstone Investment Advisors LLC	13,066	$48K	0.0%	N/A	0.018%
11/14/2024	Martingale Asset Management L P	24,712	$91K	0.0%	N/A	0.035%
11/13/2024	FMR LLC	5,075,837	$18.68M	0.0%	-41.5%	7.138%
11/12/2024	49 Wealth Management LLC	22,558	$83K	0.0%	+81.7%	0.032%
11/12/2024	Charles Schwab Investment Management Inc.	406,210	$1.50M	0.0%	-13.3%	0.571%
11/9/2024	Primecap Management Co. CA	1,498,030	$5.51M	0.0%	+21.6%	2.107%
11/9/2024	Intech Investment Management LLC	20,407	$75K	0.0%	N/A	0.029%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	229,138	$0.84M	0.0%	+126.3%	0.322%
11/5/2024	Aigen Investment Management LP	11,054	$41K	0.0%	N/A	0.016%
11/5/2024	GSA Capital Partners LLP	608,585	$2.24M	0.2%	+138.5%	0.856%
11/4/2024	Los Angeles Capital Management LLC	59,805	$0.22M	0.0%	-28.6%	0.084%
11/1/2024	Carson Advisory Inc.	24,570	$90K	0.1%	+55.8%	0.035%
10/25/2024	China Universal Asset Management Co. Ltd.	13,676	$50K	0.0%	+63.9%	0.019%
10/24/2024	Wealth Enhancement Advisory Services LLC	67,893	$0.25M	0.0%	+44.3%	0.095%
10/10/2024	Exchange Traded Concepts LLC	45,506	$0.17M	0.0%	+195.3%	0.064%
10/3/2024	SG Americas Securities LLC	26,149	$96K	0.0%	+84.8%	0.037%
8/16/2024	Algert Global LLC	19,119	$78K	0.0%	N/A	0.027%
8/15/2024	Decheng Capital LLC	3,070,442	$12.56M	3.8%	+46.2%	4.323%
8/14/2024	Squarepoint Ops LLC	148,755	$0.61M	0.0%	+543.8%	0.209%
8/14/2024	Bank of Montreal Can	98,331	$0.40M	0.0%	N/A	0.138%
8/14/2024	Profund Advisors LLC	30,892	$0.13M	0.0%	-33.4%	0.043%
8/12/2024	XTX Topco Ltd	178,465	$0.73M	0.1%	+1,581.9%	0.251%
8/12/2024	E Fund Management Co. Ltd.	10,177	$42K	0.0%	-27.7%	0.014%
8/9/2024	Primecap Management Co. CA	1,232,340	$5.04M	0.0%	+5.8%	1.735%
8/9/2024	Renaissance Technologies LLC	661,682	$2.71M	0.0%	+152.6%	0.932%
8/9/2024	Dimensional Fund Advisors LP	626,663	$2.56M	0.0%	-13.4%	0.882%
8/8/2024	Federated Hermes Inc.	482,481	$1.97M	0.0%	-75.9%	0.679%
8/8/2024	American Century Companies Inc.	23,312	$95K	0.0%	N/A	0.033%
8/6/2024	Los Angeles Capital Management LLC	83,717	$0.34M	0.0%	+117.6%	0.118%
8/3/2024	TD Asset Management Inc	102,880	$0.42M	0.0%	-60.3%	0.145%
8/1/2024	Rhumbline Advisers	94,213	$0.39M	0.0%	+13.8%	0.133%
7/31/2024	Anfield Capital Management LLC	9,767	$40K	0.0%	N/A	0.014%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	7,809	$32K	0.0%	-50.0%	0.011%
7/26/2024	Bank of New York Mellon Corp	333,719	$1.37M	0.0%	+15.1%	0.470%
7/19/2024	Values First Advisors Inc.	74,925	$0.31M	0.2%	+5.4%	0.105%
7/12/2024	SG Americas Securities LLC	14,152	$58K	0.0%	N/A	0.020%
5/29/2024	Opaleye Management Inc.	200,000	$3.15M	0.7%	N/A	0.282%
5/16/2024	California State Teachers Retirement System	50,395	$0.79M	0.0%	-6.0%	0.071%
5/16/2024	Kennedy Capital Management LLC	11,978	$0.19M	0.0%	N/A	0.017%
5/15/2024	Price T Rowe Associates Inc. MD	3,489,709	$55M	0.0%	+20.2%	4.913%
5/10/2024	Vanguard Group Inc.	4,398,625	$69.32M	0.0%	-17.8%	6.194%
5/8/2024	Entropy Technologies LP	17,573	$0.28M	0.0%	-56.5%	0.025%
5/8/2024	ProShare Advisors LLC	15,436	$0.24M	0.0%	+9.0%	0.022%
5/7/2024	49 Wealth Management LLC	10,662	$0.17M	0.0%	N/A	0.015%
5/3/2024	Carson Advisory Inc.	12,770	$0.20M	0.1%	N/A	0.018%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	31,587	$0.52M	0.0%	-22.1%	0.045%
4/30/2024	Commonwealth Equity Services LLC	60,895	$0.96M	0.0%	+12.2%	0.086%
4/29/2024	China Universal Asset Management Co. Ltd.	13,634	$0.22M	0.0%	+66.5%	0.019%
4/16/2024	Wealth Enhancement Advisory Services LLC	43,175	$0.68M	0.0%	N/A	0.061%
4/5/2024	Los Angeles Capital Management LLC	38,468	$0.61M	0.0%	N/A	0.054%
2/20/2024	Eventide Asset Management LLC	11,559,975	$175.13M	2.9%	+47.9%	16.291%
2/15/2024	Birchview Capital LP	16,000	$0.24M	0.2%	N/A	0.023%
2/14/2024	Pennant Investors LP	32,400	$0.49M	0.1%	N/A	0.046%
2/14/2024	Verition Fund Management LLC	344,617	$5.22M	0.0%	-35.9%	0.487%
2/14/2024	Sectoral Asset Management Inc.	7,355	$0.11M	0.0%	-98.1%	0.010%
2/13/2024	Tower Research Capital LLC TRC	3,615	$55K	0.0%	+252.3%	0.005%
2/13/2024	Capital International Investors	2,819,664	$42.72M	0.0%	-9.9%	3.984%
2/13/2024	Rafferty Asset Management LLC	360,125	$5.46M	0.0%	+79.4%	0.509%
2/12/2024	Decheng Capital LLC	2,099,583	$31.81M	8.9%	N/A	2.967%
2/12/2024	TD Asset Management Inc	190,168	$2.88M	0.0%	+5.2%	0.269%
2/9/2024	Primecap Management Co. CA	1,023,350	$15.50M	0.0%	-1.0%	1.446%
2/9/2024	Quest Partners LLC	2,482	$38K	0.0%	N/A	0.004%
2/7/2024	Teacher Retirement System of Texas	11,425	$0.17M	0.0%	-18.5%	0.016%
2/7/2024	E Fund Management Co. Ltd.	19,340	$0.29M	0.0%	+87.6%	0.027%
2/6/2024	Charles Schwab Investment Management Inc.	445,823	$6.75M	0.0%	+0.9%	0.630%
2/6/2024	Swiss National Bank	97,400	$1.48M	0.0%	-10.1%	0.138%
2/1/2024	Handelsbanken Fonder AB	13,500	$0.21M	0.0%	N/A	0.019%
1/31/2024	abrdn plc	40,156	$0.61M	0.0%	N/A	0.057%
1/31/2024	Federated Hermes Inc.	2,160,565	$32.73M	0.1%	+10.9%	3.053%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	40,574	$0.62M	0.0%	+17.1%	0.057%
1/24/2024	China Universal Asset Management Co. Ltd.	8,188	$0.12M	0.0%	+352.6%	0.012%
1/23/2024	Regency Capital Management Inc. DE	29,800	$0.45M	0.3%	+98.7%	0.042%
1/18/2024	Values First Advisors Inc.	48,068	$0.73M	0.4%	+17.5%	0.068%
1/12/2024	SG Americas Securities LLC	152,747	$2.31M	0.0%	+4.3%	0.216%
1/11/2024	OneAscent Financial Services LLC	10,324	$0.16M	0.0%	N/A	0.015%
1/5/2024	Exchange Traded Concepts LLC	5,989	$91K	0.0%	+34.0%	0.008%
12/18/2023	Vanguard Group Inc.	5,236,663	$105.05M	0.0%	+6.2%	7.400%
12/1/2023	Wellington Management Group LLP	1,917,105	$38.46M	0.0%	+0.5%	2.709%
11/15/2023	Sectoral Asset Management Inc.	386,525	$7.75M	1.5%	+65.2%	0.546%
11/15/2023	Kennedy Capital Management LLC	156,475	$3.14M	0.1%	+2.7%	0.221%
11/15/2023	Adage Capital Partners GP L.L.C.	301,667	$6.05M	0.0%	-45.6%	0.426%
11/15/2023	Alps Advisors Inc.	52,125	$1.05M	0.0%	+19.2%	0.074%
11/14/2023	Eventide Asset Management LLC	7,814,039	$156.75M	2.8%	+13.6%	11.041%
11/14/2023	Avidity Partners Management LP	2,100,000	$42.13M	1.7%	-10.0%	2.967%
11/14/2023	Qube Research & Technologies Ltd	141,388	$2.84M	0.0%	N/A	0.200%
11/14/2023	Trexquant Investment LP	24,516	$0.49M	0.0%	-39.4%	0.035%
11/14/2023	Primecap Management Co. CA	1,033,750	$20.74M	0.0%	-7.0%	1.461%
11/14/2023	Profund Advisors LLC	34,176	$0.69M	0.0%	-24.9%	0.048%
11/13/2023	Federated Hermes Inc.	1,947,693	$39.07M	0.1%	-3.5%	2.752%

Data available starting January 2016

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $3.47

$3.36

$4.00

50 Day Range

MA: $3.42

$2.70

$4.36

52 Week Range

Now: $3.47

$2.66

$18.07

Volume

1,832,087 shs

Average Volume

1,566,191 shs

Market Capitalization

$247.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

Who are the company insiders with the largest holdings of Zentalis Pharmaceuticals?: Zentalis Pharmaceuticals' top insider investors include:
Matrix Capital Management Comp (Major Shareholder)
Kevin D Bunker (Insider)
Cam Gallagher (President)
Cam Gallagher (CFO)
Melissa B Epperly (CFO)
Diana Hausman (Insider)
Kimberly Blackwell (CEO)
David Michael Johnson (Director)
Carrie Brownstein (Insider)
Jan Skvarka (Director)
Vincent Vultaggio (Insider)
Learn More about top insider investors at Zentalis Pharmaceuticals.
Who are the major institutional investors of Zentalis Pharmaceuticals?: Zentalis Pharmaceuticals' top institutional shareholders include:
FMR LLC — 7.14%
Verition Fund Management LLC — 2.12%
Primecap Management Co. CA — 2.11%
Geode Capital Management LLC — 1.81%
State Street Corp — 1.75%
GSA Capital Partners LLP — 0.86%
Learn More about top institutional investors of Zentalis Pharmaceuticals stock.
Which major investors are selling Zentalis Pharmaceuticals stock?: In the last quarter, ZNTL stock was sold by these institutional investors:
FMR LLC
State Street Corp
Y Intercept Hong Kong Ltd
Charles Schwab Investment Management Inc.
Geode Capital Management LLC
Los Angeles Capital Management LLC
Jane Street Group LLC
Within the last year, company insiders that have sold Zentalis Pharmaceuticals company stock include:
Matrix Capital Management Comp (Major Shareholder)
Kevin D Bunker (Insider)
Cam Gallagher (President)
Cam Gallagher (CFO)
Melissa B Epperly (CFO)
Learn More investors selling Zentalis Pharmaceuticals stock.
Which major investors are buying Zentalis Pharmaceuticals stock?: In the last quarter, ZNTL stock was purchased by institutional investors including:
Verition Fund Management LLC
GSA Capital Partners LLP
Primecap Management Co. CA
Connor Clark & Lunn Investment Management Ltd.
PDT Partners LLC
Exchange Traded Concepts LLC
Martingale Asset Management L P
Wealth Enhancement Advisory Services LLC
During the previous year, these company insiders have bought Zentalis Pharmaceuticals stock:
Matrix Capital Management Comp (Major Shareholder)
Kevin D Bunker (Insider)
Cam Gallagher (President)
Learn More investors buying Zentalis Pharmaceuticals stock.

Let’s be blunt

From DTI | Ad

Check out the $100 Challenge now